BioAge Labs and Novartis Ink $500M Deal to Tackle Aging-Related Diseases
BioAge Labs, a clinical-stage biopharmaceutical company developing therapies targeting the biology of aging, announced a multi-year collaboration with Novartis worth over $500 million. The partnership aims to identify and validate drug targets for treating diseases related to aging by combining BioAge’s proprietary human longevity datasets with Novartis’ expertise in exercise biology and drug discovery.
Topics: Startups & Deals